Literature DB >> 24989669

Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?

Elena Antelmi1, Giovanni Rizzo, Margherita Fabbri, Sabina Capellari, Cesa Scaglione, Paolo Martinelli.   

Abstract

Cellular mechanism leading to Parkinson Disease (PD) is still unknown, but impairment of lysosomal degradation of aberrant proteins seems to play a crucial role. The most known lysosomal disease associated with PD is Gaucher Disease. However, actually a number of different lysosomal disorders have been linked with PD. We report three families with Arylsulphatase A partial deficit in which we can find a high recurrence of parkinsonism among the siblings. The pedigree members show as well some atypical signs and symptoms among the PD spectrum features. Arylsulphatase A plays a crucial role in protein degradation. Even if a possibly casual association cannot be excluded, it can be speculated that Arylsulphatase A partial deficit can act as a cofactor for neurodegeneration in subjects with other genetic or environmental predispositions to PD or to other neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989669     DOI: 10.1007/s00415-014-7425-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Increased incidence of Parkinson disease among relatives of patients with Gaucher disease.

Authors:  Assaf Halperin; Deborah Elstein; Ari Zimran
Journal:  Blood Cells Mol Dis       Date:  2006-05-02       Impact factor: 3.039

2.  Neuropsychological assessment of mental deterioration: purpose of a brief battery and a probabilistic definition of "normality" and "non-normality".

Authors:  R Gallassi; P Lenzi; A Stracciari; S Lorusso; C Ciardulli; A Morreale; V Mussuto
Journal:  Acta Psychiatr Scand       Date:  1986-07       Impact factor: 6.392

3.  Reduced activity of arylsulfatase A and predisposition to neurological disorders: analysis of 140 pediatric patients.

Authors:  S Sangiorgi; A Ferlini; A Zanetti; M Mochi
Journal:  Am J Med Genet       Date:  1991-09-01

4.  Occurrence of Parkinson's syndrome in type I Gaucher disease.

Authors:  O Neudorfer; N Giladi; D Elstein; A Abrahamov; T Turezkite; E Aghai; A Reches; B Bembi; A Zimran
Journal:  QJM       Date:  1996-09

5.  Localization of phosphorylated ERK/MAP kinases to mitochondria and autophagosomes in Lewy body diseases.

Authors:  Jian-Hui Zhu; Fengli Guo; John Shelburne; Simon Watkins; Charleen T Chu
Journal:  Brain Pathol       Date:  2003-10       Impact factor: 6.508

6.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

7.  Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers.

Authors:  C Marras; B Schüle; B Schuele; R P Munhoz; E Rogaeva; J W Langston; M Kasten; C Meaney; C Klein; P M Wadia; S-Y Lim; R S-I Chuang; C Zadikof; T Steeves; K M Prakash; R M A de Bie; G Adeli; T Thomsen; K K Johansen; H A Teive; A Asante; W Reginold; A E Lang
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

8.  Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course.

Authors:  Núria Setó-Salvia; Javier Pagonabarraga; Henry Houlden; Berta Pascual-Sedano; Oriol Dols-Icardo; Arianna Tucci; Coro Paisán-Ruiz; Antonia Campolongo; Sofía Antón-Aguirre; Inés Martín; Laia Muñoz; Enric Bufill; Lluïsa Vilageliu; Daniel Grinberg; Mónica Cozar; Rafael Blesa; Alberto Lleó; John Hardy; Jaime Kulisevsky; Jordi Clarimón
Journal:  Mov Disord       Date:  2011-12-15       Impact factor: 10.338

9.  Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease.

Authors:  Adriana Sánchez-Danés; Yvonne Richaud-Patin; Iria Carballo-Carbajal; Senda Jiménez-Delgado; Carles Caig; Sergio Mora; Claudia Di Guglielmo; Mario Ezquerra; Bindiben Patel; Albert Giralt; Josep M Canals; Maurizio Memo; Jordi Alberch; José López-Barneo; Miquel Vila; Ana Maria Cuervo; Eduard Tolosa; Antonella Consiglio; Angel Raya
Journal:  EMBO Mol Med       Date:  2012-03-08       Impact factor: 12.137

10.  The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease.

Authors:  Raquel Duran; Niccolo E Mencacci; Aikaterini V Angeli; Maryam Shoai; Emma Deas; Henry Houlden; Atul Mehta; Derralynn Hughes; Timothy M Cox; Patrick Deegan; Anthony H Schapira; Andrew J Lees; Patricia Limousin; Paul R Jarman; Kailash P Bhatia; Nicholas W Wood; John Hardy; Tom Foltynie
Journal:  Mov Disord       Date:  2012-12-05       Impact factor: 10.338

View more
  4 in total

Review 1.  The Role of Lipids in Parkinson's Disease.

Authors:  Helena Xicoy; Bé Wieringa; Gerard J M Martens
Journal:  Cells       Date:  2019-01-07       Impact factor: 6.600

Review 2.  Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease.

Authors:  Silvia Paciotti; Elisabetta Albi; Lucilla Parnetti; Tommaso Beccari
Journal:  J Clin Med       Date:  2020-02-21       Impact factor: 4.241

Review 3.  Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features.

Authors:  Nattakarn Limphaibool; Piotr Iwanowski; Marte Johanne Veilemand Holstad; Katarzyna Perkowska
Journal:  Front Neurol       Date:  2018-10-12       Impact factor: 4.003

Review 4.  Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson's Disease.

Authors:  Shani Blumenreich; Or B Barav; Bethan J Jenkins; Anthony H Futerman
Journal:  Int J Mol Sci       Date:  2020-07-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.